Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR 03_A ctDNA screening and randomized phase II study in HR+, HER2- metastatic breast cancer
2022-502372-22-01Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ribociclib, alpelisib and fulvestrant in breast cancer (3 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival (PFS) in randomized patients. Started Jul 2023; status: completed.
02
Drugs
ribociclibalpelisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-502372-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502372-22-01.